

Journal Pre-proof

In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China

Fei Shao Shuang Xu Xuedi Ma Zhouting Xu Jiayou Lyu Michael
Ng Hao Cui Changxiao Yu Qing Zhang Peng Sun Ziren Tang



PII: S0300-9572(20)30142-8

DOI: <https://doi.org/doi:10.1016/j.resuscitation.2020.04.005>

Reference: RESUS 8482

To appear in: *Resuscitation*

Received Date: 2 April 2020

Accepted Date: 6 April 2020

Please cite this article as: Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, Cui H, Yu C, Zhang Q, Sun P, Tang Z, In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China, *Resuscitation* (2020), doi: <https://doi.org/10.1016/j.resuscitation.2020.04.005>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

1 **In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in**
2 **Wuhan, China**

3
4 Authors' name: Fei Shao ^{a,b}, Shuang Xu ^c, Xuedi Ma ^d, Zhouming Xu ^d, Jiayou Lyu ^d, Michael
5 Ng ^e, Hao Cui ^b, Changxiao Yu ^b, Qing Zhang ^f, Peng Sun ^{c,#}, Ziren Tang ^{a,b,#}

6
7 Authors' addresses:

8 ^a Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chaoyang
9 Hospital, Beijing, China

10 ^b Department of Emergency Medicine, Beijing Chaoyang Hospital, Capital Medical University,
11 Beijing, China

12 ^c Department of Emergency Medicine, Union Hospital, Tongji Medical College, Huazhong
13 University of Science and Technology, Wuhan, China

14 ^d AI Research Division, A.I. Phoenix Technology Co., Ltd, Hong Kong, China

15 ^e Research Division for Mathematical and Statistical Science, University of Hong Kong, Hong
16 Kong, China

17 ^f Departments of Anaesthesiology, Union Hospital, Tongji Medical College, Huazhong
18 University of Science and Technology, Wuhan, China

19
20 [#] These authors contributed equally

21
22 **Corresponding author**

23 Name: Ziren Tang, MD, PhD

24 Address: Department of Emergency Medicine, Beijing Chaoyang Hospital, #8 Worker's
25 Stadium South Road, Chaoyang District, Beijing 100020, China

26 Telephone: +86 13601105812

27 Email: tangziren1970@163.com

28

29 **And**

30

31 Name: Peng Sun, MD, PhD

32 Address: Department of Emergency Medicine, Union Hospital, Tongji Medical College,

33 Huazhong University of Science and Technology, No.1277 Jiefang DaDao, Wuhan 430022,

34 Hubei Province, China.

35 Telephone: +86 13971648169

36 Email: simple1111@hust.edu.cn

37

38 **Word count of the paper: 2400 (without abstract and references)**

39

40 **Word count of the Abstract: 249**

41

42 **Abstract**

43 **Objective:** To describe the characteristics and outcomes of patients with severe COVID-19 and
44 in-hospital cardiac arrest (IHCA) in Wuhan, China.

45 **Methods:** The outcomes of patients with severe COVID-19 pneumonia after IHCA over a
46 40-day period were retrospectively evaluated. Between January 15 and February 25, 2020, data
47 for all cardiopulmonary resuscitation (CPR) attempts for IHCA that occurred in a tertiary
48 teaching hospital in Wuhan, China were collected according to the Utstein style. The primary
49 outcome was restoration of spontaneous circulation (ROSC), and the secondary outcomes were
50 30-day survival, and neurological outcome.

51 **Results:** Data from 136 patients showed 119 (87.5 %) patients had a respiratory cause for their
52 cardiac arrest, and 113 (83.1%) were resuscitated in a general ward. The initial rhythm was
53 asystole in 89.7%, pulseless electrical activity (PEA) in 4.4%, and shockable in 5.9%. Most
54 patients with IHCA were monitored (93.4%) and in most resuscitation (89%) was initiated <1
55 min. The average length of hospital stay was 7 days and the time from illness onset to hospital
56 admission was 10 days. The most frequent comorbidity was hypertension (30.2%), and the
57 most frequent symptom was shortness of breath (75%). Of the patients receiving CPR, ROSC
58 was achieved in 18 (13.2%) patients, 4 (2.9%) patients survived for at least 30 days, and one
59 patient achieved a favourable neurological outcome at 30 days. Cardiac arrest location and
60 initial rhythm were associated with better outcomes.

61 **Conclusion:** Survival of patients with severe COVID-19 pneumonia who had an in-hospital
62 cardiac arrest was poor in Wuhan.

63
64 **Keywords:** In-hospital cardiac arrest, Cardiopulmonary resuscitation, COVID-19, ROSC,
65 Survival

66

67 **Introduction**

68 Since the outbreak of a novel coronavirus resulting in coronavirus disease 2019 (COVID-19) in
69 Wuhan, China at the end of 2019, there have been more than 820,000 individuals in more than
70 170 countries with confirmed COVID-19, of whom more than 40,000 have died by April 1,
71 2020¹. Several studies have already reported the clinical course and outcomes of patients with
72 COVID-19 pneumonia²⁻⁶. The mortality of critically ill patients and risk factors for a poor
73 prognosis have been assessed; however, the identification of risk factors and assessment of
74 outcomes of patients with COVID-19 after in-hospital cardiac arrest (IHCA) remain unknown.

75
76 Therefore, in this study, we aimed to present the clinical characteristics; clinical outcomes,
77 including return of spontaneous circulation (ROSC); and 30-day survival of patients with
78 laboratory confirmed COVID-19 pneumonia after IHCA at Union hospital in Wuhan. We
79 identified factors associated with improved outcomes following IHCA in patients with
80 COVID-19.

81

82 **Methods**

83

84 *Study design*

85 This was a single-centred, retrospective, observational study. We identified patients who had
86 IHCA between January 15 and February 25, 2020 in Union Hospital in Wuhan. The eligibility
87 criteria were as follows: patients aged 14 years or older and patients with IHCA who were
88 diagnosed with severe COVID-19 pneumonia according to the interim guidelines from the
89 World Health Organization. All enrolled inpatients had a definite outcome after IHCA,
90 including death, ROSC, and 30-day survival. The study was approved by the Ethics Committee
91 Boards of Beijing Chaoyang Hospital, Capital Medical University, and Union Hospital, Tongji
92 Medical College, and Huazhong University of Science and Technology, and the requirement

93 for informed consent was waived.

94

95 *Setting*

96 The west campus of Union hospital, which is a teaching tertiary hospital in Wuhan, was
97 one of the designated hospitals for patients with severe COVID-19 pneumonia. In total, 800
98 beds were modified as isolation wards and opened for admission to severe patients with
99 COVID-19 pneumonia starting from January 2020. In addition to the 800-current staff (doctors
100 nurses and others) of the hospital, over 2000 staff from 12 other provinces were employed to
101 provide medical care on the general wards and intensive care unit (ICU) of Union hospital.
102 There was a rapid response team available 24/7 to attempt resuscitation for patients with IHCA;
103 this team was also in charge of tracheal intubation and cardiopulmonary resuscitation (CPR) in
104 the general ward when needed. The team were alerted using a pager system. Resuscitation
105 followed guidelines from the American Heart Association and International Liaison Committee
106 on Resuscitation for advanced cardiac life support and post-resuscitation care. Ward staff
107 (usually nurses) started CPR and if defibrillation prior to team arrival. All staff (clinical and
108 non-clinical) working on the general ward, ICU and rapid response team donned personal
109 protective equipment (PPE) at the beginning of their shift. For all settings this included
110 protective clothing, a N95 mask and visor. Due to the exertion required of doing continuous
111 chest compressions whilst wearing PPE, the person doing compressions was changed after at
112 most one minute. A mechanical chest compression device was not available.

113

114 *Data collection*

115 We collected demographic, clinical, and outcome data of treated patients with severe
116 COVID-19 pneumonia and IHCA from an electronic medical record according Utstein style
117 guidelines during the 40 days⁷.

118

119 Cardiac arrest was defined as the cessation of cardiac mechanical activity as confirmed by the
120 absence of signs of circulation. ‘Treated IHCA’ refers to a patient who experienced a cardiac
121 arrest and was treated with chest compressions and/or defibrillation. Details regarding treated
122 cases were collected by the physicians and entered into a database. We collected information
123 on age and sex of the patient; locations where IHCA occurred; witness and monitor status;
124 initial ECG rhythm such as shockable rhythm (ventricular fibrillation [VF], and pulseless VT)
125 or non-shockable rhythm (PEA and asystole); information on the response interval; and
126 presumed aetiology of the IHCA, which was categorised as cardiac, respiratory, and other.
127 Information regarding clinical symptoms, treatments, time from illness onset to hospital
128 admission, comorbidity, and length of hospital stay were also recorded.

129
130 The primary outcome was immediate survival with any ROSC, which was defined by return
131 of circulation in the absence of ongoing chest compressions (return of adequate pulse/heart rate
132 by palpation, auscultation, Doppler, arterial blood pressure waveform, or documented systolic
133 blood pressure >50 mmHg). The secondary outcome was 30-day survival and neurological
134 outcomes at 30 days recorded by cerebral performance category (CPC) score. Survival with
135 favourable neurological outcome was defined as CPC score of 1 or 2.

136

137 *Statistical methods*

138 Continuous variables are reported as means or median with interquartile ranges (IQRs) as
139 appropriate. Categorical variables are reported as numbers and percentages of patients in each
140 category. We stratified patients according to survival status. The chi-square test was used to
141 examine baseline differences in demographics and clinical characteristics across the strata of
142 resuscitation durations. A p-value <0.05 was considered statistically significant. The odds ratio
143 and 95% confidence interval were accordingly calculated. All analyses were conducted using
144 Python, version 3.6 (Python Software Foundation).

145 **Results**

146

147 Totally, we reviewed 761 records of patients with severe COVID-19 and identified 151
148 patients who had an IHCA during the study period of 40 days. After exclusions, a total of 136
149 patients were resuscitated and documented using the Utstein template (Fig. 1). The
150 characteristics of the included patients are shown in Table 1. Of these patients, 110 (80.9%)
151 were aged over 60 years and 46 (33.8%) were women. The most frequent comorbidity was
152 hypertension (30.2%), followed by diabetes (19.9%) and coronary heart disease (11.0%) (Table
153 1).

154

155 Of 136 patients who were resuscitated, most patients had a respiratory aetiology (119 cases),
156 whereas the remaining had cardiac aetiology (10 cases) and other causes (7 cases) (Table 1).
157 The initial cardiac arrest rhythm was VF or pulseless VT in 8 (5.9%) cases, PEA in 6 (4.4%),
158 and asystole in 122 (89.7%) (Table 1).

159

160 Of 136 patients resuscitated, 113 (83.1%) were in the general ward at the time of IHCA, while
161 23 (16.9 %) of the resuscitation efforts were initiated in the ICU (Table 1). Nearly all patients
162 had electrocardiogram (ECG) and pulse oximetry monitoring (93.4%) before their cardiac
163 arrest and in most cases resuscitation (89%) was initiated in <1 min. The length of hospital stay
164 was 7 (IQR, 4–11) days, and the time from illness onset to hospital admission was 10 (IQR,
165 7–14) days (Table 1).

166

167 The most frequent symptom was shortness of breath (75%), followed by
168 myalgia/arthritis (60.3%) and cough (52.2%). Fever on admission was observed only in 52
169 (38.2%) cases (Table 1).

170

171 Of 136 patients who underwent resuscitation efforts, ROSC was achieved in 18 (13.2%)
172 patients, of which four patients were still alive at 30 days.
173 Resuscitation in the ICU resulted in better outcome when compared with that for the general
174 ward. Of the eight patients with an initial rhythm of VF or pulseless VT, six achieved ROSC,
175 whereas in patients with an initial rhythm of asystole, 9% achieved ROSC. The location and
176 initial rhythm between patients with different survival statuses were statistically significantly
177 different (Table 2, Supplementary Table). Only one patient achieved a favourable neurological
178 outcome at 30 days after IHCA. The overall mortality rate was 19.3% in patients with severe
179 COVID-19 pneumonia during the 40-day study period.

180

181 **Discussion**

182 To our knowledge, this is the first study to report the clinical characteristics and outcomes of
183 patients with severe COVID-19 pneumonia and IHCA using the Utstein style for reporting
184 IHCA events. In our study population, most patients with IHCA (96.3%) underwent attempted
185 resuscitation; however, there were five cases where the patients' relatives had requested no
186 resuscitation attempt be made if cardiac arrest occurred.

187 The most frequent underlying comorbidity of patients in our study was hypertension
188 followed by diabetes mellitus and coronary heart disease. This was consistent with other
189 reports in Wuhan. The common symptoms such as fever, shortness of breath,
190 myalgia/arthralgia, and cough were also similar to that of previous studies.

191 It is commonly accepted that the outcome after IHCA is more favourable when the initial
192 monitored rhythm is VF/VT rather than non-VF/VT (i.e., asystole or PEA). Most of the initial
193 monitored rhythms recorded by responders in our survey of patients who experienced an IHCA
194 were asystole (89.7 % of cases), which is more common than described in previous reports of
195 IHCA.⁸⁻¹⁰ A shockable rhythm was recorded in only 5.9% of cases (2.7% of ward cases [3
196 patients], 22% of ICU cases [5 patients]), but the outcome among these patients was better

197 than those with asystole or PEA.

198 There have been differences reported in previous studies regarding the mortality rate of
199 patients with COVID-19. A retrospective cohort study in Wuhan reported that 54 of 191
200 patients died in the hospital, and older age, higher SOFA score, and elevated d-dimer at
201 admission were risk factors for death of adults with COVID-19². In another report from Wuhan,
202 the mortality rate was 62% among critically ill patients with COVID-19 and 81% among those
203 requiring mechanical ventilation³. Meanwhile, Washington state, USA reported a mortality rate
204 of 67%, and 24% of the patients remained critically ill and 9.5% were discharged from the
205 ICU¹¹. We observed an overall mortality rate of 19.3% in patients with severe COVID-19
206 pneumonia during the study period. The difference may be due to the severity of patients
207 enrolled in the analysis, management of intensive care, and the capacity of hospitalisation for
208 patients.

209 The overall outcome of IHCA in our study was poor, with a ROSC rate of 13.2% and
210 30-day survival rate of 2.9%. The shortage of medical resources and uncertain quality of CPR
211 were key factors in the resuscitation of patients with severe COVID-19 pneumonia in Wuhan.
212 As COVID-19 spread, the number of critically ill patients exceeded the capacity of ICUs in
213 most hospitals in Wuhan. It was not rare for critically patients to stay in the general ward with
214 limited advanced life-support facilities. With an improvement in recognition and protection
215 strategies, two newly constructed hospitals and several isolation hospitals were soon brought
216 into service. As Union hospital was designated for patients with severe pneumonia, the
217 defibrillation and advanced airway interventions and mechanical ventilation could be
218 established in the general ward with the help of a 24/7 rapid response team. Although a
219 growing number of mechanical compression devices had been introduced in hospitals, there
220 was still a significant lack of intensive care resources. In addition, few patients had
221 do-not-attempt CPR (DNACPR) decision. The patients were cared for in isolation wards, and
222 visiting by relatives was very limited. Only five patients who had a cardiac arrest had a

223 DNACPR decision. We did not make any DNACPR decisions without discussion with a
224 relative.

225 According to recent international CPR guidelines, post-resuscitation care has been added
226 to the ‘chain of survival’, and its importance to the outcome of cardiac arrests has been
227 emphasized^{12,13}. Although the World Health Organization and National Health Commission of
228 China have issued preliminary guidance on infection control, screening, and diagnosis in the
229 general population, in addition to the guidelines issued by the Surviving Sepsis Campaign
230 COVID-19 panel who provided recommendations to support hospital clinicians managing
231 critically ill adults with COVID-19, there is still limited guidance based on clinical research on
232 the acute management of critically ill patients with COVID-19^{14,15}. Supportive care is the
233 mainstay of treatment among patients with severe COVID-19 pneumonia. In our study, there
234 were numerous patients with severe pneumonia who were resuscitated in the general ward,
235 resulting in a poor outcome when compared with those who received intensive care in the ICU.
236 The difficulties in managing rapid deterioration, acute respiratory failure and acute respiratory
237 distress syndrome in a general ward setting may have also contributed to the poor outcomes.

238 Based on our observations, chest compressions with PPE require considerable effort, and
239 the person doing compressions should change every minute. In addition, the PPE clothing
240 should be loose fitting to enable compressions and movement. The use of a mechanical chest
241 compression device should be considered if prolonged compressions are required.

242 This study had some limitations. First, many data points in the resuscitation process were
243 not documented, such as duration of resuscitation efforts, time to first defibrillation, and
244 time to first epinephrine. Second, we do not know the precise interventions that patients had
245 prior to cardiac arrest. Third, this study involved only one centre and the results may not be
246 generalisable to other settings and healthcare systems. The relatively few cases and survivors
247 means that our confidence in our estimates of outcome is low. To explore the risk factors for
248 outcome, univariable and multivariable logistic regression models were applied, but no

249 significant difference were found. More studies are needed to better understand the incidence
250 and outcomes of acute respiratory distress syndrome and critical illnesses caused by
251 COVID-19, which will be important for critical care management and resource planning.
252 Finally, a lack of data regarding CPR quality is also a limitation. It was also difficult to identify
253 the differences between general wards that were managed by staff from different hospitals.
254 These variations in resuscitation efforts and post-arrest care could also affect the survival
255 outcomes and results. Finally, although we did not study this formally, we are not aware of any
256 clinical staff involved in a resuscitation attempt becoming infected with COVID-19 as a result
257 of their involvement.

258

259 **Conclusions**

260 The overall ROSC and 30-day survival rates of IHCA patients with severe COVID-19
261 pneumonia in Wuhan were poor. Factors associated with ROSC and 30-day survival were
262 initial rhythm and location of arrest. Providing care for patients at risk of cardiac arrest in an
263 intensive care setting, should be considered to improve the outcome of IHCA patients with
264 severe COVID-19 pneumonia.

265 **Conflicts of interest**

266 None.

267 **Acknowledgements**

268 We thank all colleagues who collected and computed medical information of the patients
269 included in this study. We thank the patients and their families for making this study possible.
270 We also thank all the healthcare providers of Union hospital, as well as the supporting teams
271 from 12 province for resuscitation efforts. We would like to express our very great appreciation
272 to other colleagues of A.I. Phoenix Technology Co., Ltd: Peng Zhao, Jiwen You, Yuwei Liu,
273 Shihao Wang, and Yunfei Tang, who contributed a lot throughout the process of data cleaning
274 and analytics. This insightful work would not have been possible without their passions and
275 efforts. This study was supported by National Nature Science Foundation of China (No.
276 81571866) and National Science & Technology Fundamental Resource Investigation Program
277 of China (No. 2018FY100600). The funding sources were not involved in the study design,
278 collection, analysis, and data interpretation, or manuscript submission for publication.

279

280

281

282 **References**

- 283 1. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports.
284 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>
285 (Assessed on April 1st, 2020)
- 286 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
287 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;
288 6736:1-9.
- 289 3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
290 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
291 observational study. *Lancet Respir Med* 2020; 2600:1-7.
- 292 4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with
293 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020:1-9.
- 294 5. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in
295 China. *N Engl J Med* 2020:1-13.
- 296 6. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research
297 Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J*
298 *Med* 2020; 382:727-33.
- 299 7. Nolan JP, Berg RA, Andersen LW, et al. Cardiac Arrest and Cardiopulmonary
300 Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Template
301 for In-Hospital Cardiac Arrest. A Consensus Report From a Task Force of the
302 International Liaison Committee on Resuscitation. *Resuscitation* 2019:1-12.
- 303 8. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019
304 Update: A report from the American Heart Association. *Circulation* 2019;139: e56-e28.
- 305 9. Bradley SM, Kaboli P, Kamphuis LA, Chan PS, Iwashyna TJ, Nallamothu BK.
306 Temporal trends and hospital-level variation of in-hospital cardiac arrest incidence and
307 outcomes in the Veterans Health Administration. *Am Heart J* 2017; 193:117-123.

- 308 10. Shao F, Li CS, Liang LR, et al. Incidence and outcome of adult in-hospital cardiac arrest
309 in Beijing, China. *Resuscitation*. 2016;102.
- 310 11. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients
311 with COVID-19 in Washington State. *JAMA* 2020; 4720:2019-2021.
- 312 12. Perkins GD, Neumar R, Monsieurs KG, et al. The International Liaison Committee on
313 Resuscitation—Review of the last 25 years and vision for the future. *Resuscitation* 2017;
314 121:104-116.
- 315 13. Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary 2010 American
316 Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency
317 Cardiovascular Care. *Circulation* 2010;122: S640-S656.
- 318 14. Waleed A, Morten HM, Yaseen MA, et al. Surviving sepsis campaign: Guidelines on
319 the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Crit*
320 *Care Med* 2020; doi:10.1097/CCM.0000000000004363
- 321 15. National Health Commission of the People’s Republic of China. New diagnosis and
322 treatment scheme for novel coronavirus infected pneumonia (Trial edition 7). 2020
323

324 **Table 1. Characteristics of patients with severe COVID-19 pneumonia and in-hospital**
 325 **cardiac arrest in Wuhan**

Variables	Overall (N = 136)
Sex	
Female (%)	46 (33.8)
Male (%)	90 (66.2)
Age, years	
Mean	69
Range, IQR	61-77
Age group, years, n (%)	
14-18	1 (0.7)
19-29	2 (1.5)
30-39	2(1.5)
40-49	3 (2.2)
50-59	18 (13.2)
60-69	46 (33.8)
70-79	39 (28.7)
>=80	25 (18.4)
Aetiology, n (%)	
Cardiac	10 (7.4)
Respiratory	119 (87.5)
Others	7 (5.1)
Location, n (%)	
ICU	23 (16.9)
General ward	113 (83.1)
Initial rhythm, n (%)	
VF/VT	8 (5.9)
PEA	6 (4.4)
Asystole	122 (89.7)
Time to initiation of CPR, n (%)	

≤1 min	121 (89.0)
2-4 min	12 (8.8)
≥5 min	3 (2.2)

Witnessed, n (%)

Yes	132 (97.1)
No	4 (2.9)

Monitored, n (%)

Yes	127 (93.4)
No	9 (6.6)

Comorbidity, n (%)

Hypertension	41 (30.2)
Diabetes	27 (19.9)
Coronary heart disease	15 (11.0)
Cancer	10 (7.4)
COPD	6 (4.4)
Cerebrovascular disease	5 (3.7)
Chronic renal disease	3 (2.2)
Others	5 (3.7)

Length of hospital stay, median, days (IQR)

7 (4-11)

Time from illness onset to hospital admission, median days (IQR)

10 (7-14)

Symptom, n (%)

Fever on admission	52 (38.2)
Shortness of breath	102 (75.0)
Myalgia/arthralgia	82 (60.3)
Cough	71 (52.2)
Fatigue	66 (48.5)
Sputum	48 (35.3)
Abnormality of mentality	45 (33.1)
Diarrhoea	27 (19.9)

Nausea/vomiting	14 (10.3)
Headache/dizziness	9 (6.6)
Abdominal pain	8 (5.9)

326 IQR, interquartile range; ROSC, return of spontaneous circulation; ICU, intensive care unit;
327 CPR, cardiopulmonary resuscitation; PEA, pulseless electrical activity; VF, ventricular
328 fibrillation; VT, ventricular tachycardia; COPD, chronic obstructive pulmonary disease.
329

330 **Table 2. Outcomes of patients with severe COVID-19 pneumonia and in-hospital cardiac**
 331 **arrest in Wuhan**

Group	N	ROSC			30-day survival		
		n (%)	p-Value	OR (95% CI)	n (%)	p-Value	OR (95% CI)
Age, years			0.08			0.19	
>60	105	11 (10.5)		1.00	2(1.9)		1.00
≤60	31	7 (22.6)		0.40(0.13-1.37)	2(6.5)		0.28(0.02-4.09)
Sex			0.12			0.15	
Female	46	9 (19.6)		1.00	0 (0)		1.00
Male	90	9 (10)		0.46 (0.17-1.25)	4 (4.4)		4.28 (0.22-82.71)
Location			<0.01			<0.01	
General ward	113	8 (7.1)		1.00	1(1)		1.00
ICU	23	10 (43.5)		10.10 (3.38-30.14)	3 (13)		16.80 (1.663-169.70)
Witnessed			0.43			0.72	
No	4	0 (0)		1.000	0 (0)		1.00
Yes	132	18 (13.6)		1.26 (0.06-24.91)	4 (3)		0.25 (0.01-5.57)
Aetiology			0.48			0.36	
Cardiac	10	2 (20)		1.000	1(10)		1.00
Respiratory	119	16 (13.4)		0.62 (0.12-3.19)	3 (2.5)		0.23 (0.02-2.47)
Others	7	0 (0)		0.29 (0.01-7.45)	0 (0)		0.64 (0.02-22.06)
Initial rhythm			<0.01			<0.01	
VF/VT	8	6 (75.0)		1.000	3 (37.5)		1.00
PEA	6	1 (16.7)		0.07 (0.01-0.97)	0 (0)		0.14 (0.01-3.48)
Asystole	122	11 (9)		0.03 (0.01-0.18)	1 (0.8)		0.01 (0.00-0.16)

332 ROSC, return of spontaneous circulation; OR, odds ratio; CI, confidence interval; ICU,
 333 Intensive Care Unit; PEA, pulseless electrical activity; VF, ventricular fibrillation; VT,
 334 pulseless ventricular tachycardia.

335
 336
 337

338 **Figure legend**

339 **Figure 1. Flow diagram illustrating the number of patients during the study with respect**
340 **to the location of cardiac arrests.** ROSC, return of spontaneous circulation; ICU, intensive
341 care unit; DNAR, do-not-attempt-resuscitation.

342

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Ziren Tang, MD, PhD

Department of Emergency Medicine, Beijing Chaoyang Hospital, #8 Worker's Stadium South Road,
Chaoyang District, Beijing 100020, China

Telephone: +86 13601105812

Email: tangziren1970@163.com

Journal Pre-proof